Skip to content
Bored Studies
RecruitingPhase 1

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Regeneron Pharmaceuticals · NCT06975787

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–60 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
90
US sites recruiting
3
Study start
December 22, 2025
Record last updated
September 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).

The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.

This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Being studied: Vonsetamig; Odronextamab

Conditions: Lupus Nephritis (LN)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key General Inclusion Criteria

  • Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
  • Participant must have refractory or relapsed disease, as described in the protocol

Key General Exclusion Criteria

  • History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization
  • Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
  • Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening

NOTE: Other protocol defined inclusion/exclusion criteria apply

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
All phase 1 studies in California →
Dose Escalation Study With Bispecific Antibodies in Adult… (NCT06975787) | Bored Studies